FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1982525091> ?p ?o ?g. }

• W1982525091 abstract "Bendamustine is a bifunctional alkylating agent with proven activity in myeloma. In this study 60 newly diagnosed myeloma patients were given bendamustine plus bortezomib and prednisone in a regimen consisting of one cycle of bortezomib twice weekly for 6 weeks (1.3 mg/m(2) on days 1, 4, 8, 11, 22, 25, 29, and 32), plus bendamustine (90 mg/m(2) on days 1 and 4) and prednisone. The following cycles included bortezomib once weekly. Patients who were transplant candidates proceeded to stem cell collection after four cycles and the transplant was performed after six cycles. Patients who were not candidates for transplantation received up to nine cycles. Forty-two patients were transplant candidates and after six cycles, 50% achieved at least a very good partial response, with 24% having complete responses; 35 proceeded to a transplant, and the complete response rate was 54%. Seventeen patients continued up to nine cycles, and 57% achieved at least a very good partial response, including 26% with complete responses. The 2-year progression-free survival and overall survival rates were 62% and 86%, respectively. The safety profile was manageable, but stem cell mobilization was compromised in 35% of patients. In summary, this combination is effective in untreated patients, with an acceptable toxicity profile, but given the introduction of second-generation novel agents and monoclonal antibodies, the combination will probably be better reserved for relapsing patients, in whom stem cell collection is not needed, while cost-effective combinations with non-cross-resistant drugs continue to represent a medical need. This trial was registered with ClinicalTrials.gov, number NCT01376401." @default.
• W1982525091 created "2016-06-24" @default.
• W1982525091 creator A5005731938 @default.
• W1982525091 creator A5013568680 @default.
• W1982525091 creator A5015898454 @default.
• W1982525091 creator A5016479494 @default.
• W1982525091 creator A5020420490 @default.
• W1982525091 creator A5020989412 @default.
• W1982525091 creator A5029159537 @default.
• W1982525091 creator A5029238392 @default.
• W1982525091 creator A5030665606 @default.
• W1982525091 creator A5031837957 @default.
• W1982525091 creator A5034182883 @default.
• W1982525091 creator A5034430204 @default.
• W1982525091 creator A5047672322 @default.
• W1982525091 creator A5051903959 @default.
• W1982525091 creator A5054952877 @default.
• W1982525091 creator A5057553435 @default.
• W1982525091 creator A5059428070 @default.
• W1982525091 creator A5070122487 @default.
• W1982525091 creator A5071261900 @default.
• W1982525091 creator A5080697191 @default.
• W1982525091 creator A5088242526 @default.
• W1982525091 date "2015-04-24" @default.
• W1982525091 modified "2023-10-18" @default.
• W1982525091 title "Bendamustine, bortezomib and prednisone for the treatment of newly diagnosed multiple myeloma patients: results of a prospective phase 2 Spanish/Pethema trial" @default.
• W1982525091 cites W1546245187 @default.
• W1982525091 cites W1963575145 @default.
• W1982525091 cites W1978449163 @default.
• W1982525091 cites W1986692982 @default.
• W1982525091 cites W1999177459 @default.
• W1982525091 cites W2000125803 @default.
• W1982525091 cites W2003734726 @default.
• W1982525091 cites W2028195916 @default.
• W1982525091 cites W2039496823 @default.
• W1982525091 cites W2059405721 @default.
• W1982525091 cites W2059895867 @default.
• W1982525091 cites W2063697325 @default.
• W1982525091 cites W2074340459 @default.
• W1982525091 cites W2074533771 @default.
• W1982525091 cites W2086653135 @default.
• W1982525091 cites W2096207943 @default.
• W1982525091 cites W2123516278 @default.
• W1982525091 cites W2125396994 @default.
• W1982525091 cites W2127192057 @default.
• W1982525091 cites W2134902298 @default.
• W1982525091 cites W2141105112 @default.
• W1982525091 cites W2159771593 @default.
• W1982525091 cites W2609515889 @default.
• W1982525091 doi "https://doi.org/10.3324/haematol.2015.124818" @default.
• W1982525091 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5004426" @default.
• W1982525091 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25911554" @default.
• W1982525091 hasPublicationYear "2015" @default.
• W1982525091 type Work @default.
• W1982525091 sameAs 1982525091 @default.
• W1982525091 citedByCount "13" @default.
• W1982525091 countsByYear W19825250912015 @default.
• W1982525091 countsByYear W19825250912016 @default.
• W1982525091 countsByYear W19825250912017 @default.
• W1982525091 countsByYear W19825250912018 @default.
• W1982525091 countsByYear W19825250912020 @default.
• W1982525091 countsByYear W19825250912021 @default.
• W1982525091 countsByYear W19825250912022 @default.
• W1982525091 crossrefType "journal-article" @default.
• W1982525091 hasAuthorship W1982525091A5005731938 @default.
• W1982525091 hasAuthorship W1982525091A5013568680 @default.
• W1982525091 hasAuthorship W1982525091A5015898454 @default.
• W1982525091 hasAuthorship W1982525091A5016479494 @default.
• W1982525091 hasAuthorship W1982525091A5020420490 @default.
• W1982525091 hasAuthorship W1982525091A5020989412 @default.
• W1982525091 hasAuthorship W1982525091A5029159537 @default.
• W1982525091 hasAuthorship W1982525091A5029238392 @default.
• W1982525091 hasAuthorship W1982525091A5030665606 @default.
• W1982525091 hasAuthorship W1982525091A5031837957 @default.
• W1982525091 hasAuthorship W1982525091A5034182883 @default.
• W1982525091 hasAuthorship W1982525091A5034430204 @default.
• W1982525091 hasAuthorship W1982525091A5047672322 @default.
• W1982525091 hasAuthorship W1982525091A5051903959 @default.
• W1982525091 hasAuthorship W1982525091A5054952877 @default.
• W1982525091 hasAuthorship W1982525091A5057553435 @default.
• W1982525091 hasAuthorship W1982525091A5059428070 @default.
• W1982525091 hasAuthorship W1982525091A5070122487 @default.
• W1982525091 hasAuthorship W1982525091A5071261900 @default.
• W1982525091 hasAuthorship W1982525091A5080697191 @default.
• W1982525091 hasAuthorship W1982525091A5088242526 @default.
• W1982525091 hasBestOaLocation W19825250911 @default.
• W1982525091 hasConcept C126322002 @default.
• W1982525091 hasConcept C141071460 @default.
• W1982525091 hasConcept C143998085 @default.
• W1982525091 hasConcept C2776364478 @default.
• W1982525091 hasConcept C2776694085 @default.
• W1982525091 hasConcept C2777478702 @default.
• W1982525091 hasConcept C2778720950 @default.
• W1982525091 hasConcept C2779050716 @default.
• W1982525091 hasConcept C2779338263 @default.
• W1982525091 hasConcept C2780653079 @default.
• W1982525091 hasConcept C2780775027 @default.
• W1982525091 hasConcept C2781413609 @default.
• W1982525091 hasConcept C2781442060 @default.
• W1982525091 hasConcept C2911091166 @default.

• next